WO2018004498A1 - Combinaisons d'anti-inflammatoire non stéroïdien (ains) et d'un antagoniste du récepteur h2 pour le traitement de la douleur et de l'inflammation - Google Patents

Combinaisons d'anti-inflammatoire non stéroïdien (ains) et d'un antagoniste du récepteur h2 pour le traitement de la douleur et de l'inflammation Download PDF

Info

Publication number
WO2018004498A1
WO2018004498A1 PCT/TR2017/050259 TR2017050259W WO2018004498A1 WO 2018004498 A1 WO2018004498 A1 WO 2018004498A1 TR 2017050259 W TR2017050259 W TR 2017050259W WO 2018004498 A1 WO2018004498 A1 WO 2018004498A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
pain
famotidine
etodolac
receptor antagonist
Prior art date
Application number
PCT/TR2017/050259
Other languages
English (en)
Inventor
Mehmet Nevzat PISAK
Original Assignee
Imuneks Farma Ilac San. Ve Tic. A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imuneks Farma Ilac San. Ve Tic. A.S. filed Critical Imuneks Farma Ilac San. Ve Tic. A.S.
Publication of WO2018004498A1 publication Critical patent/WO2018004498A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

La présente invention concerne une composition pharmaceutique comprenant au moins un agent anti-inflammatoire non stéroïdien (AINS) qui inhibe sélectivement le cyclooxygénase-2 (COX-2) en combinaison avec au moins un antagoniste du récepteur H2 dans une forme de dosage pharmaceutique unitaire unique. La composition pharmaceutique de la présente invention est utile pour le traitement de l'inflammation et de la douleur.
PCT/TR2017/050259 2016-06-30 2017-06-13 Combinaisons d'anti-inflammatoire non stéroïdien (ains) et d'un antagoniste du récepteur h2 pour le traitement de la douleur et de l'inflammation WO2018004498A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2016/09256 2016-06-30
TR201609256 2016-06-30

Publications (1)

Publication Number Publication Date
WO2018004498A1 true WO2018004498A1 (fr) 2018-01-04

Family

ID=59966809

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2017/050259 WO2018004498A1 (fr) 2016-06-30 2017-06-13 Combinaisons d'anti-inflammatoire non stéroïdien (ains) et d'un antagoniste du récepteur h2 pour le traitement de la douleur et de l'inflammation

Country Status (1)

Country Link
WO (1) WO2018004498A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019135725A1 (fr) * 2018-01-03 2019-07-11 Pisak Mehmet Nevzat Combinaisons d'anti-inflammatoires non stéroïdiens (ains) inhibiteurs sélectifs de cox-2 et d'antagonistes des récepteurs h2 pour le traitement rapide de la douleur et de l'inflammation
CN114699380A (zh) * 2021-12-27 2022-07-05 南京联智医药科技有限公司 一种依托度酸片及其制备方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204118A (en) 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
WO2002098352A2 (fr) * 2001-06-01 2002-12-12 Pozen Inc. Compositions pharmaceutiques destinees a la liberation coordonnee d'ains
US20070154542A1 (en) * 2005-12-30 2007-07-05 Cogentus Pharmaceuticals, Inc. Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
US20070237820A1 (en) 2004-01-21 2007-10-11 Andrx Pharmaceuticals, Llc Pharmaceutical formulations containing a non-steroidal antinflammatory drug and an antiulcerative drug
WO2008027963A2 (fr) * 2006-08-31 2008-03-06 Horizon Therapeutics, Inc. Formulations à dose unique d'ains avec antagonistes du récepteur de h2, et procédés d'utilisation
US20090233970A1 (en) 2008-03-11 2009-09-17 Nickell Robert P Combined nsaid and acid blocker formulation and method
WO2012173581A1 (fr) * 2011-03-21 2012-12-20 Ak Kimya Ithalat-Ihracat Ve Sanayii A.S. Combinaisons de thiocolchicoside, étodolac et famotidine
WO2013169218A1 (fr) * 2012-05-08 2013-11-14 Mahmut Bilgic Compositions pharmaceutiques de s-étodolac

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204118A (en) 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
US5417980A (en) 1989-11-02 1995-05-23 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
WO2002098352A2 (fr) * 2001-06-01 2002-12-12 Pozen Inc. Compositions pharmaceutiques destinees a la liberation coordonnee d'ains
EP1411900B1 (fr) 2001-06-01 2010-07-21 Pozen, Inc. Compositions pharmaceutiques destinees a la liberation coordonnee d'ains
US20070237820A1 (en) 2004-01-21 2007-10-11 Andrx Pharmaceuticals, Llc Pharmaceutical formulations containing a non-steroidal antinflammatory drug and an antiulcerative drug
US20070154542A1 (en) * 2005-12-30 2007-07-05 Cogentus Pharmaceuticals, Inc. Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
WO2008027963A2 (fr) * 2006-08-31 2008-03-06 Horizon Therapeutics, Inc. Formulations à dose unique d'ains avec antagonistes du récepteur de h2, et procédés d'utilisation
US20090233970A1 (en) 2008-03-11 2009-09-17 Nickell Robert P Combined nsaid and acid blocker formulation and method
WO2012173581A1 (fr) * 2011-03-21 2012-12-20 Ak Kimya Ithalat-Ihracat Ve Sanayii A.S. Combinaisons de thiocolchicoside, étodolac et famotidine
WO2013169218A1 (fr) * 2012-05-08 2013-11-14 Mahmut Bilgic Compositions pharmaceutiques de s-étodolac

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SABATE, E.: "Adherence to Long- Term Therapies: Evidence for Action", 2003, WORLD HEALTH ORGANIZATION, pages: 212

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019135725A1 (fr) * 2018-01-03 2019-07-11 Pisak Mehmet Nevzat Combinaisons d'anti-inflammatoires non stéroïdiens (ains) inhibiteurs sélectifs de cox-2 et d'antagonistes des récepteurs h2 pour le traitement rapide de la douleur et de l'inflammation
CN114699380A (zh) * 2021-12-27 2022-07-05 南京联智医药科技有限公司 一种依托度酸片及其制备方法

Similar Documents

Publication Publication Date Title
TWI388316B (zh) 抑制胃酸分泌之組合物及方法
JP2004508396A (ja) 非ステロイド性抗炎症薬およびプロトンポンプ阻害薬を含有する医薬製剤
JP2011057714A (ja) 胃酸分泌阻害組成物
EP2797584B1 (fr) Combinaisons de diacéréine et d'anti-inflammatoires non stéroïdiens
WO2012173581A1 (fr) Combinaisons de thiocolchicoside, étodolac et famotidine
JP2008533127A5 (fr)
KR102024699B1 (ko) 클로피도그렐 및 아스피린을 포함하는 복합제제
EP1462098B1 (fr) Composition pharmaceutique stabilisée comprenant une NSAID et une prostaglandine
KR20190092805A (ko) 아세틸살리실산 및 란소프라졸을 포함하는 약학적 조성물
WO2018004498A1 (fr) Combinaisons d'anti-inflammatoire non stéroïdien (ains) et d'un antagoniste du récepteur h2 pour le traitement de la douleur et de l'inflammation
JP2006506376A (ja) テナトプラゾール及び抗炎症剤を組み合わせた医薬組成物
JP2016512493A5 (fr)
CA2725437C (fr) Compositions et procedes d'inhibition de la secretion d'acide gastrique
US20060198886A1 (en) Medicament having coated methenamine combined with acidifier
ZA200606409B (en) Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic
US20110117070A1 (en) Compositions and methods for treating headache
US11648240B2 (en) Pharmaceutical composition comprising famotidine, lidocaine and melatonin
US20120003274A1 (en) Oral sustained release antidepressant formulation
CN109498811A (zh) 一种含钾离子竞争性酸阻滞剂和非甾体抗炎药的复方制剂
WO2019135725A1 (fr) Combinaisons d'anti-inflammatoires non stéroïdiens (ains) inhibiteurs sélectifs de cox-2 et d'antagonistes des récepteurs h2 pour le traitement rapide de la douleur et de l'inflammation
JP2009510139A (ja) 組合せ
WO2018231175A2 (fr) Anti-inflammatoires non stéroïdiens et combinaisons d'antagonistes du récepteur h2 pour le traitement de la douleur et de l'inflammation
WO2019098984A1 (fr) Combinaison synergique de diclofénac, de famotidine et d'un carbonate
JP2006076956A (ja) 胃炎の治療・予防用配合剤
CN112933091B (zh) 一种抗胃酸类疾病的药物组合物及应用

Legal Events

Date Code Title Description
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17772498

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17772498

Country of ref document: EP

Kind code of ref document: A1